![E3353_06 [ALT4bxxx].png](https://static.wixstatic.com/media/73af19_0b90f98cbdf94c8b808d8ee2921668a0~mv2.png/v1/fill/w_921,h_928,al_c,q_90,usm_0.66_1.00_0.01,enc_auto/E3353_06%20%5BALT4bxxx%5D.png)
We are at the forefront
of innovation, driving the
next generation of
oncological drug discovery through cutting-edge technology
In our pursuit to create faster and more effective treatments, we have pioneered the use of Large Language Models (LLMs) to enhance the development of immunotherapies, particularly in oncology.
Our proprietary platform, EMLy™, integrates machine learning with human expertise to predict and engineer therapeutic T Cell Receptors (TCRs) and monoclonal antibodies (mAbs).
In this presentation, we will showcase how we leverage EMLy™ and its advanced LLM capabilities to harvest unique oncology targets, optimize drug candidates, and accelerate the drug discovery process. By focusing on long-term cancer survivors, we aim to unlock novel targets that can lead to breakthrough treatments.
This document is password protected. Please complete the contact form below and we'll email you the password.
Join us in our journey
...as we explore how Etcembly is transforming the landscape of cancer treatment with AI-driven solutions.
